Vaishali Pharma

Why is Vaishali Pharma Ltd falling/rising?

As of 26-Aug, Vaishali Pharma Ltd's stock price is rising to 8.17, driven by positive short-term performance and attractive valuations. However, its long-term outlook is uncertain due to historical underperformance and weak fundamentals.

As of 26-Aug, Vaishali Pharma Ltd's stock price is rising, currently at 8.17, reflecting an increase of 0.2 or 2.51%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.22% today, indicating positive market sentiment. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a bullish trend in the short to medium term.<BR><BR>Moreover, the company reported positive financial results on June 26, showcasing the highest Return on Capital Employed (ROCE) at 8.38% and an operating profit to net sales ratio of 6.51%. These metrics highlight improved operational efficiency and profitability. The stock is also trading at a discount compared to its peers' average historical valuations, making it an attractive option for investors.<BR><BR>However, it is important to note that despite the recent rise, the stock has experienced significant declines over the past year, with a return of -31.29%. This long-term underperformance against benchmarks, combined with weak fundamental strengths such as a low average ROCE of 7.02% and poor growth in net sales and operating profit over the last five years, raises concerns about its sustainability. Additionally, a notable drop in investor participation, with delivery volume falling by 47.7% against the 5-day average, may indicate waning interest.<BR><BR>In summary, while Vaishali Pharma Ltd is currently experiencing a rise in stock price due to positive short-term performance and attractive valuations, the long-term outlook remains uncertain due to historical underperformance and weak fundamentals.

Which are the latest news on Vaishali Pharma?

Should I buy, sell or hold Vaishali Pharma Ltd?

Who are in the management team of Vaishali Pharma?

The management team of Vaishali Pharma includes Atul Vasani (Chairman & Managing Director), Jagruti Vasani (Whole-time Director), Dewansh Vasani (Executive Director), and independent directors Ashvin Jamnadas Ganatra, Manish Bhagwandas Ved, and Pratik Vikram Jakhelia, along with Company Secretary Vishwa Mekhia. They oversee the company's operations and strategic direction.

The management team of Vaishali Pharma includes the following individuals:<BR><BR>1. **Atul Vasani** - Chairman & Managing Director<BR>2. **Jagruti Vasani** - Whole-time Director<BR>3. **Dewansh Vasani** - Executive Director<BR>4. **Ashvin Jamnadas Ganatra** - Independent Director<BR>5. **Manish Bhagwandas Ved** - Independent Director<BR>6. **Vishwa Mekhia** - Company Secretary & Compliance Officer<BR>7. **Pratik Vikram Jakhelia** - Independent Director<BR><BR>This team plays a crucial role in overseeing the company's operations and strategic direction.

What does Vaishali Pharma do?

Vaishali Pharma Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2008. As of March 2026, it reported net sales of 27 Cr and a net profit of 0 Cr, with a market cap of INR 110 Cr.

Overview: <BR>Vaishali Pharma Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Vaishali Pharma Limited was incorporated in 2008 as a Private Limited Company and underwent a business acquisition on July 1, 2008, merging the operations of a proprietorship concern owned by its promoter, Mr. Atul Vasani. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 27 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 110 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.25 <BR>Return on Equity: 5.84% <BR>Price to Book: 1.57 <BR><BR>Contact Details: <BR>Address: 706 to 709 7th Floor Aravali, Business Centre Borivali(W) Mumbai Maharashtra : 400092 <BR>Tel: 91-22-28928833 <BR>Email: investor@vaishalipharma.com <BR>Website: http://www.vaishalipharma.com

Who are the peers of the Vaishali Pharma?

Vaishali Pharma's peers include Balaxi Pharma, Krebs Biochem, Sotac Pharma, and others, with varying management risks and growth rates. Its 1-year return is -30.29%, better than Balaxi Pharma's -50.79% but worse than Krebs Biochem's -26.32%.

Peers: The peers of Vaishali Pharma are Balaxi Pharma, Krebs Biochem, Sotac Pharma, Tyche Industries, Godavari Drugs, Pharmaids Pharma, Concord Drugs, Kimia Bioscien., Mercury Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Balaxi Pharma and Mercury Labs, while Average management risk is found at Tyche Industries, Godavari Drugs, and the rest. Below Average management risk is noted at Vaishali Pharma, Sotac Pharma, Pharmaids Pharma, Concord Drugs, Kimia Bioscien., and the rest. Growth is Below Average at Balaxi Pharma, Vaishali Pharma, Godavari Drugs, Concord Drugs, Kimia Bioscien., and the rest, while Average growth is seen at Sotac Pharma and Pharmaids Pharma. Capital Structure is Excellent at Balaxi Pharma and Tyche Industries, Average at Sotac Pharma, and Below Average at Vaishali Pharma, Godavari Drugs, Pharmaids Pharma, Concord Drugs, Kimia Bioscien., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krebs Biochem at -26.32%, while the peer with the lowest is Balaxi Pharma at -50.79%. Vaishali Pharma's 1-year return is -30.29%, which is better than Balaxi Pharma but worse than Krebs Biochem. Additionally, peers with a negative six-month return include Krebs Biochem, Sotac Pharma, and Godavari Drugs.

How big is Vaishali Pharma?

As of 14th August, Vaishali Pharma Ltd has a market capitalization of 111.15 Cr, with recent net sales of 85.03 Cr and a net profit of 2.92 Cr over the last three quarters.

As of 14th August, <BR><BR>Market Cap: Vaishali Pharma Ltd has a market capitalization of 111.15 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest three quarters is 85.03 Cr, while the sum of Net Profit for the same period is 2.92 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 64.92 Cr and Total Assets valued at 109.66 Cr.

Are Vaishali Pharma Ltd latest results good or bad?

Vaishali Pharma Ltd's latest Q4 FY26 results are concerning, with a 68.94% drop in net profit and negative operating margins, indicating operational distress and reliance on unsustainable non-operating income. Overall, the performance suggests significant challenges for the company's sustainability.

Vaishali Pharma Ltd's latest results for Q4 FY26 indicate significant challenges for the company. While net sales increased by 9.25% quarter-on-quarter to ₹26.93 crores, the consolidated net profit plummeted by 68.94% to just ₹0.41 crores. This stark decline in profitability raises concerns, especially given that the operating margin turned negative at -0.74%, a drastic fall from a positive margin of 6.33% in the previous quarter.<BR><BR>The company's reliance on non-operating income is alarming, with other income accounting for 700% of profit before tax, suggesting that the reported profitability is not sustainable and heavily dependent on non-core activities. Additionally, the return on equity (ROE) is at 5.98%, which is below the industry average, indicating poor capital efficiency.<BR><BR>Overall, the financial performance reflects operational distress, with negative operating margins and significant volatility in revenue. The combination of these factors suggests that the latest results are not good, and the company faces serious questions regarding its business sustainability moving forward.

How has been the historical performance of Vaishali Pharma?

Vaishali Pharma has experienced fluctuating financial performance, with net sales increasing from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, but significant declines in profitability and negative cash flow in March 2025. Despite growth in total assets and a reduction in debt, the company's operating profit margin and profits before and after tax have sharply decreased.

Answer:<BR>The historical performance of Vaishali Pharma shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Vaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was as high as 13.09% in March 2023, fell sharply to 0.1% in March 2025. Profit before tax also declined significantly from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025, while profit after tax decreased from INR 6.60 crore to INR 0.82 crore in the same period. The company's total assets increased from INR 66.08 crore in March 2020 to INR 109.66 crore in March 2025, reflecting growth in shareholder's funds, which rose to INR 64.92 crore. Despite this growth, total debt decreased from INR 14.72 crore in March 2020 to INR 8.50 crore in March 2025. Cash flow from operating activities has been negative in March 2025 at INR -18.00 crore, contrasting with positive cash flows in previous years. Overall, Vaishali Pharma's financial performance indicates a complex trajectory with growth in sales and assets but challenges in profitability and cash flow management.

Who are the top shareholders of the Vaishali Pharma?

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani with 21.1%, and Sapan Anil Shah as the highest public shareholder at 6.82%. Individual investors own 65.24% of the company, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani, who holds the largest stake at 21.1%. The highest public shareholder is Sapan Anil Shah, with a holding of 6.82%. Additionally, individual investors collectively own 65.24% of the company. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

Is Vaishali Pharma overvalued or undervalued?

As of February 7, 2025, Vaishali Pharma is considered overvalued and risky, with a high PE ratio of 137.42, a PEG ratio of 9.89, and an EV to EBITDA ratio of 149.40, indicating unfavorable valuation metrics compared to its peers and a stock return of -7.57% versus the Sensex's 7.87%.

As of 7 February 2025, Vaishali Pharma's valuation grade has moved from very expensive to risky, indicating a shift in perception regarding its market position. The company is currently overvalued, as evidenced by its high PE ratio of 137.42 and a PEG ratio of 9.89, which suggests that the stock price is not justified by its earnings growth potential. Additionally, the EV to EBITDA ratio stands at 149.40, highlighting significant concerns about profitability relative to enterprise value.<BR><BR>In comparison to its peers, Vaishali Pharma's valuation metrics appear unfavorable; for instance, its PE ratio is significantly higher than the industry average, suggesting that investors are paying a premium for its shares. Notably, the company has underperformed relative to the Sensex over the past year, with a stock return of -7.57% compared to the Sensex's 7.87%. Given these factors, Vaishali Pharma is positioned as overvalued in the current market landscape.

What is the technical trend for Vaishali Pharma?

As of June 4, 2025, Vaishali Pharma's technical trend is mildly bearish, supported by moving averages and Bollinger Bands, despite a mildly bullish weekly MACD.

As of 4 June 2025, the technical trend for Vaishali Pharma has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands and moving averages on the weekly and daily time frames are all signaling mildly bearish conditions. The KST is mildly bullish weekly but also mildly bearish monthly, and the Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the moving averages and Bollinger Bands.

When is the next results date for Vaishali Pharma?

No Upcoming Board Meetings

What is the bonus history of the Vaishali Pharma?

Vaishali Pharma has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced for October 15, 2024. Previously, a 3:5 bonus was issued on October 18, 2019.

Vaishali Pharma has a notable bonus history. The most recent bonus issue was announced as a 1:1 bonus, with an ex-date of October 15, 2024. Prior to that, the company issued a bonus in a 3:5 ratio, with the record date on October 18, 2019, and an ex-date of October 17, 2019. This indicates that Vaishali Pharma has actively engaged in rewarding its shareholders through bonus shares in the past.

Has Vaishali Pharma declared dividend?

No Dividend History Available